Merck KGaA (OTCMKTS:MKGAF) Shares Down 3.6% – Time to Sell?

Shares of Merck KGaA (OTCMKTS:MKGAF) dropped 3.6% on Thursday . The company traded as low as $151.46 and last traded at $151.46. Approximately 77 shares traded hands during trading, a decline of 87% from the average session volume of 610 shares. The stock had previously closed at $157.0460.

Merck KGaA Trading Down 1.2%

The company has a market cap of $20.05 billion, a PE ratio of 23.69 and a beta of 0.96. The company has a current ratio of 1.31, a quick ratio of 0.84 and a debt-to-equity ratio of 0.27. The stock has a 50 day moving average price of $161.87 and a 200 day moving average price of $149.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MASTERINVEST Kapitalanlage GmbH purchased a new position in shares of Merck KGaA in the 2nd quarter worth about $4,896,000. Puzo Michael J bought a new stake in Merck KGaA during the 2nd quarter valued at about $2,230,000. Somerville Kurt F bought a new stake in Merck KGaA during the 2nd quarter valued at about $1,997,000. Pinnacle Holdings LLC purchased a new position in Merck KGaA in the second quarter worth about $1,487,000. Finally, North Star Asset Management Inc. bought a new position in shares of Merck KGaA in the second quarter worth approximately $1,411,000. Institutional investors own 0.10% of the company’s stock.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.

The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.